A key strategic priority for the Group is the delivery and strength of the pipeline. The following chart outlines the timeline, status and progress of the major projects. Collectively the pipeline is expected to deliver in excess of £40 million annual sales assuming all products reach maturity.

First Expected Launch(1)	Therapeutic Category	Species	Territory	Manufacturing	Pre-Clinical	Clinical	File
2014	Lameness(2)	Horse	International	Outsourced
2015	Anti-microbials	Several	EU	Outsourced
	Endocrinology(3)	Dogs	International	In-house
	Anti-microbials	Poultry	EU	In-house
	Endocrinology	Dogs	EU	Outsourced
2016	Anti-microbials	Several	EU	In-house
	Endocrinology(3)	Dogs	International	In-house
2017	Anti-microbials	Cattle	EU	In-house
	Dermatology	Dogs	International	In-house
	Anti-microbials	Poultry	EU	In-house
2018+	Ophthalmology	Dogs	International	Outsourced
	Anti-microbials	Poultry	EU	In-house
	Cardiovascular	Dogs	EU	In-house
	Endocrinology	Cats	International	Outsourced
	Endocrinology	Dogs	International	In-house
	Dermatology	Dogs	US	In-house

(1) Calendar year (2) Osphos (3) Identical product with first launch in EU and subsequent launch in US

The first expected launch date is a management estimate that may not be met due to regulatory, manufacturing or other issues.